Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1

被引:103
作者
Huang, Chen [1 ,2 ,3 ]
Li, Haidong [1 ,4 ]
Wu, Weidong [1 ]
Jiang, Tao [1 ]
Qiu, Zhengjun [1 ,2 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 1, Dept Gen Surg, Shanghai 200080, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Key Lab Pancreat Dis, Shanghai 200080, Peoples R China
[3] Shanghai Jiao Tong Univ, Pancreat Canc Ctr, Shanghai 200080, Peoples R China
[4] Shanghai Tongji Univ, Affiliated East Hosp, Dept Gen Surg, Shanghai 200120, Peoples R China
基金
中国国家自然科学基金;
关键词
pancreatic cancer; invasion; miR-155; STAT3; BREAST-CANCER; EXPRESSION; MICRORNA-155; GROWTH; PROGRESSION; INHIBITION; SURVIVAL; INVASION; TUMORS; BETA;
D O I
10.3892/or.2013.2576
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the present study, we investigated the effects of miR-155 on pancreatic cancer cell invasion and migration in vitro, underlying gene expression, expression of miR-155 and its target genes in pancreatic cancer tissues, and their association with metastasis and clinical stage. miR-155 mimics and an inhibitor were transfected into Panc-1 and Capan-2 cells in order to regulate the expression of miR-155. qPCR and western immunoblotting were performed in order to detect gene expression. Transwell assays were performed to characterize the invasion and migration of pancreatic cancer cells in vitro. Immunohistochemical analysis and in situ hybridization were used to detect the expression of protein and microRNA in pancreatic cancer tissue. miR-155 mimics and an inhibitor upregulated and downregulated, respectively, the expression of miR-155 in pancreatic cancer cells. The invasion and migration of pancreatic cancer cells increased or decreased along with miR-155 expression in vitro. Suppressor of cytokine signaling 1 (SOCS1) protein expression was upregulated when miR-155 was inhibited and downregulated when miR-155 was increased. However, the expression of P-signal transducer and activator of transcription-3 (STAT3) was synchronized with that of miR-155. Transcription of SOCS1 and STAT3 was unchanged by miR-155 regulation. miR-155 expression was high in pancreatic cancer tissues and SOCS1 expression was high in tumor-adjacent tissues. There was no relationship between these genes in cancer and tumor-adjacent tissues. In addition, miR-155 expression was associated with lymph node metastasis and clinical stage. In conclusion, miR-155 plays an important role in the regulation of pancreatic cancer cell invasion and migration by modulating the STAT3 signaling pathway and reducing SOCS1 expression in pancreatic cancer cells.
引用
收藏
页码:1223 / 1230
页数:8
相关论文
共 34 条
[1]   Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells [J].
Babar, Imran A. ;
Czochor, Jennifer ;
Steinmetz, Allison ;
Weidhaas, Joanne B. ;
Glazer, Peter M. ;
Slack, Frank J. .
CANCER BIOLOGY & THERAPY, 2011, 12 (10) :908-914
[2]   Neurotensin Signaling Activates MicroRNAs-21 and-155 and Akt, Promotes Tumor Growth in Mice, and Is Increased in Human Colon Tumors [J].
Bakirtzi, Kyriaki ;
Hatziapostolou, Maria ;
Karagiannides, Iordanes ;
Polytarchou, Christos ;
Jaeger, Savina ;
Iliopoulos, Dimitrios ;
Pothoulakis, Charalabos .
GASTROENTEROLOGY, 2011, 141 (05) :1749-U311
[3]   MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis [J].
Bloomston, Mark ;
Frankel, Wendy L. ;
Petrocca, Fabio ;
Volinia, Stefano ;
Alder, Hansjuerg ;
Hagan, John P. ;
Liu, Chang-Gong ;
Bhatt, Darshna ;
Taccioli, Cristian ;
Croce, Carlo M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (17) :1901-1908
[4]   miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting bim expression [J].
Chen, Zhen ;
Chen, Lian-Yu ;
Dai, Hai-Yan ;
Wang, Peng ;
Gao, Song ;
Wang, Kun .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (10) :3229-3235
[5]   Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice [J].
Costinean, Stefan ;
Sandhu, Sukhinder K. ;
Pedersen, Irene M. ;
Tili, Esmerina ;
Trotta, Rossana ;
Perrotti, Danilo ;
Ciarlariello, David ;
Neviani, Paolo ;
Harb, Jason ;
Kauffman, Lauren Rachel ;
Shidham, Aaditya ;
Croce, Carlo Maria .
BLOOD, 2009, 114 (07) :1374-1382
[6]   SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated dinflammation [J].
Davey, GM ;
Heath, WR ;
Starr, R .
TISSUE ANTIGENS, 2006, 67 (01) :1-9
[7]   Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development [J].
Gironella, Meritxell ;
Seux, Mylene ;
Xie, Min-Jue ;
Cano, Carla ;
Tomasini, Richard ;
Gommeaux, Julien ;
Garcia, Stephane ;
Nowak, Jonathan ;
Yeung, Man Lung ;
Jeang, Kuan-Teh ;
Chaix, Amandine ;
Fazli, Ladan ;
Motoo, Yoshiharu ;
Wang, Qing ;
Rocchi, Palma ;
Russo, Antonio ;
Gleave, Martin ;
Dagorn, Jean-Charles ;
Iovanna, Juan L. ;
Carrier, Alice ;
Pebusque, Marie-Josephe ;
Dusetti, Nelson J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (41) :16170-16175
[8]   Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival [J].
Greither, Thomas ;
Grochola, Lukasz F. ;
Udelnow, Andrej ;
Lautenschlaeger, Christine ;
Wuerl, Peter ;
Taubert, Helge .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (01) :73-80
[9]   MicroRNA miR-155 is a biomarker of early pancreatic neoplasia [J].
Habbe, Nils ;
Koorstra, Jan-Bart M. ;
Mendell, Joshua T. ;
Offerhaus, G. Johan ;
Ryu, Ji Kon ;
Feldmann, Georg ;
Mullendore, Michael E. ;
Goggins, Michael G. ;
Hong, Seung-Mo ;
Maitra, Anirban .
CANCER BIOLOGY & THERAPY, 2009, 8 (04) :340-346
[10]   Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation [J].
Han, Zhong-Bo ;
Chen, Hong-Yuan ;
Fan, Jun-Wei ;
Wu, Jun-Yi ;
Tang, Hua-Mei ;
Peng, Zhi-Hai .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (01) :153-161